Oncotarget

Research Papers:

LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer

Akihiro Miyazaki, Hiromi Nakai, Tomoko Sonoda, Yoshihiko Hirohashi, Mika K. Kaneko, Yukinari Kato, Yoshihiko Sawa _ and Hiroyoshi Hiratsuka

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:21156-21165. https://doi.org/10.18632/oncotarget.24986

Metrics: PDF 1422 views  |   HTML 2822 views  |   ?  


Abstract

Akihiro Miyazaki1,*, Hiromi Nakai1,*, Tomoko Sonoda2, Yoshihiko Hirohashi3, Mika K. Kaneko4, Yukinari Kato4,5, Yoshihiko Sawa6 and Hiroyoshi Hiratsuka1

1Department of Oral Surgery, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8543, Japan

2Department of Public Health, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8556, Japan

3Department of Pathology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo 060-8556, Japan

4Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi 980-8575, Japan

5New Industry Creation Hatchery Center, Tohoku University, Aoba-ku, Sendai, Miyagi 980-8575, Japan

6Deparment of Oral Function & Anatomy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Kita-ku 700-0914, Japan

*These authors have contributed equally to this work

Correspondence to:

Yoshihiko Sawa, email: [email protected]

Keywords: LpMab-23; predictor; podoplanin; tongue cancer; antibody

Received: October 17, 2017    Accepted: March 12, 2018    Published: April 20, 2018

ABSTRACT

Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer.

Patients and Methods: The association between LpMab-23-recognizing cancer-type PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor.

Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan–Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23-dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60% in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features.

Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24986